Aberrant activation of the cyclin D1-cyclin-dependent kinase 4/6 (CDK4/6)-Rb signalling pathway is common in oesophageal squamous cell carcinoma (ESCC). PD-0332991, a highly specific inhibitor of CDK4/6, has potent antitumour activity against many types of cancer. The purpose of this study was to examine the in vitro and in vivo antineoplastic effect of PD-0332991 against the growth and metastasis of ESCC cells.
Introduction
Oesophageal squamous cell carcinoma (ESCC), a tumour of the digestive tract, is a particularly aggressive cancer and has been ranked as the fifth leading cause of cancer-related deaths worldwide (Torre et al., 2015) . Approximately 70% of global ESCC cases occur in China (Pennathur et al., 2013) . Despite the various regimens implemented, such as chemotherapy, radiotherapy or their combinations, the 5 year overall survival rate of this disease is only 10-30% (Sakaeda et al., 2009; Nakajima and Kato, 2013) . Moreover, 20-30% of patients newly diagnosed with ESCC had distant metastasis (Quint et al., 1995) . Therefore, there is an urgent need to develop novel targeted therapeutic drugs for ESCC patients.
An immunohistochemical analysis of 90 patients with ESCC showed that cyclin D1 and cyclin-dependent kinase 4 (CDK4) were overexpressed in 28 (34.4%) and 39 (43.3%) cases, respectively (Matsumoto et al., 1999) . A comprehensive genomic analysis of 158 ESCC cases also showed that cyclin D1 and CDK4/6 were amplified in 46.4% and 23.6% of cases, respectively (Song et al., 2014) . In addition, simultaneous overexpression of cyclin D1 and CDK4 in ESCC are frequently associated with venous invasion and poor prognosis (Song et al., 2014) . Therefore, the cyclin D1-CDK4/6 complex may be an attractive therapeutic target in ESCC.
PD-0332991 (palbociclib) is an orally available, highly specific and reversible inhibitor of both CDK4 and CDK6 kinase activities (Toogood et al., 2005) . PD-0332991 exerts an anti-proliferative effect in breast and ovarian cancer cells, myeloma cells and glioblastoma cells (Finn et al., 2009; Michaud et al., 2010; Konecny et al., 2011) and in human tumour xenografts (Fry et al., 2004; Michaud et al., 2010) or in FBXO4 (+/À) mice (Lian et al., 2015) . A phase I study of PD-0332991 in patients with Rb-positive solid tumours or non-Hodgkin's lymphoma also showed that PD-0332991 is generally well tolerated (Schwartz et al., 2011) . Of note, PD-0332991 has recently been approved by the FDA for use, in combination with letrozole, as a first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (Dhillon, 2015; Finn et al., 2015; or in combination with fulvestrant for the treatment of women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (Walker et al., 2016) . Whether PD-0332991 is active against ESCC remains unknown.
In the present study, our purpose was to examine the antineoplastic effect of PD-0332991 against the ESCC cells. We discovered that PD-0332991 potently induced G1-phase arrest in ESCC cells by inhibiting CDK4/6 activities. Moreover, PD-0332991 suppressed MMP-2 expression as well as the migration and invasion of EC109 and EC9706 cells. In addition, PD-0332991 induced cellular senescence via an effect on FOXM1. Furthermore, PD-0332991 potentiated the lethality of 5-fluorouracil (5-FU) and cisplatin on ESCC cells. More importantly, the in vivo studies also demonstrated that PD-0332991 can suppress the growth and metastasis of ESCC cells in nude mice. These findings suggest that PD-0332991 is a promising candidate drug for the treatment of ESCC.
Methods

Cell culture
Human ESCC cell lines EC109, EC9706, KYSE30, KYSE140, KYSE150, KYSE410 and CE-81T were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco's modified Eagle medium (DMEM, Invitrogen) containing 100 U·mL À1 penicillin/ streptomycin, supplemented with 10% (v . v À1 ) heatinactivated FBS at 37°C in a humidified incubator containing 5% CO 2 .
Blinding and data normalization
All the data were analysed by two observers who were blinded to the group assignment of animals. Cell viability measurements and quantitative analysis of colony formation were normalized relative to control (Curtis et al., 2015) . The graph Y-axis was labelled as '% of control'.
Cell viability assay
Cell viability was determined by MTS assay (CellTiter 96 Aqueous One Solution Cell Proliferation assay; Promega, Madison, WI) as previously described (Jin et al., 2016b) . Briefly, cells were seeded in 96-well flat-bottom plates (Corning Inc., Corning, NY, USA) and incubated with various concentrations of PD-0332991 for 72 h. Twenty microlitres of MTS solution was added to each well during the last 4 h of culture. Absorbance was read on a 96-well plate reader at a wavelength of 490 nm. Control cells received DMSO (<0.1%) containing medium. The drug concentration resulting in 50% inhibition of cell growth (IC 50 ) was determined.
The combinations were assessed in serial fixed-ratio dilutions of the two drugs. The effects of combinations were estimated using the CalcuSyn software (Biosoft, Cambridge, UK). The combination index (CI) was the ratio of the combination dose to the sum of the single-agent doses at an isoeffective level. Therefore, CI < 1 indicates synergy; CI > 1, antagonism; and CI = 1, additive (Pan et al., 2010) .
Anchorage-independent growth assay
For anchorage-independence, a two-layer soft agarcontaining media was plated in 24-well flat-bottom plates (Corning Inc.) as previously described (Ismail et al., 2011) . The first layer (300 μL) was DMEM growth medium containing 0.8% agar and 10% FBS. The second layer contained 2000 cells in DMEM medium containing 0.4% agar and 10% FBS. After incubation for 10 to 14 days at 37°C in a humidified incubator, the colonies (containing ≥50 cells) were counted using an inverted phase-contrast microscope.
The cells were washed and resupended in 1 × binding buffer. Immediately after this the propidium iodide (PI) solution was added to the cell suspension, apoptosis was assessed using the FACS LSRFortessa flow cytometer and its software.
Cell-cycle analysis
For measurement of effects on the cell cycle, cells were pretreated with or without PD-0332991 for 8 h, then 20 ng·mL À1 nocodazole (Sigma-Aldrich) was added as previously described, with modifications (Tang et al., 2012) . Cells were harvested by trypsinization 16 h after addition of nocodazole, washed with PBS and fixed in 70% ethanol. PI solution (Sigma-Aldrich) was then added; the cells were incubated at room temperature for 1 h in the dark. Cell-cycle distribution was analysed using a FACS LSRFortessa flow cytometer with its software as previously described (Dai et al., 2016) .
Western blotting analysis
Western blotting analysis was performed using the whole cell lysates prepared in RIPA buffer (Jin et al., 2014) . For the detection of cytochrome c, the cytosolic fraction was prepared in digitonin extraction buffer [10 mM PIPES, 0.015% digitonin, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl and 2.5 mM EDTA. 1 × protease inhibitor cocktail (Roche, Indianapolis, IN, USA)], to which 10 mM β-glycerophosphate, 1 mM sodium orthovanadate, 10 mM NaF and 1 mM PMSF were added. Equal amounts of total proteins were separated using 10-15% SDS-PAGE and then transferred onto nitrocellulose membranes. After being blocked with 5% dried skimmed milk, the membranes were then incubated with the primary antibodies overnight. After the probing with appropriate secondary antibodies, the membranes were scanned with the Odyssey infrared imaging system (LI-COR, Lincoln, NE, USA) (Jin et al., 2016b) .
Measurement of mitochondrial transmembrane potential
ESCC cells were exposed to 10 μM PD-0332991 for different durations. After incubation with MitoTracker probes (CMXRos and MTGreen, Eugene, OR, USA), the cells were subjected to flow cytometry analysis for inner mitochondrial transmembrane potential (ΔΨm), as described previously (Shi et al., 2009 ).
Senescence-associated β-galactosidase staining Cellular senescence was assayed by measuring senescenceassociated β-galactosidase (SA-β-gal) activity. Cells were grown in 6-well flat-bottom plates (Corning Inc.) for 24 h and then treated without or with 2.5 μM PD-0332991 for 6 days. After fixation, the cells were stained overnight according to the manufacturer's protocol (Cell Signaling #9860). The percentage of SA-β-gal positive cells was determined by counting the number of positive cells present in six separate microscope fields and then normalizing the results to the control (Shi et al., 2010) .
Wound scratch assay
The wound scratch assay, a well-established method to assess cell motility in two dimensions, was performed as described previously (Chen et al., 2013 
Cell migration and invasion assays
The migration and invasion assays were performed in transwell chambers (8 μm pore size, Costar) according to the manufacturer's instructions, with modifications (Chen et al., 2013) . For the migration assay, 200 μL of serum-free medium (containing 2 × 10 4 cells) were placed into the upper chamber of each insert, while the lower compartment was filled with 600 μL of DMEM supplemented with 20% FBS. After incubation at 37°C for 48 h, the remaining tumour cells inside the upper chamber were removed with cotton swabs. The cells on the lower surface of the membrane were stained with 0.1% crystal violet after fixation with 4.0% paraformaldehyde, and then counted under a light microscope. The invasion assay was done using the same procedure, except that the inserts were coated with Matrigel to form a matrix barrier, and then 4 × 10 4 tumour cells were added to the upper chamber.
Lentiviral transduction
pLKO.1 plasmids containing shRNA sequences targeting CDK4 (shCDK4#1: TRC number: TRCN0000010520, target sequence: ACAGTTCGTGAGGTGGCTTTA; shCDK4#2: TRCN0000196698, target sequence: GAGATTACTTTGCTGC CTTAA) and CDK6 (shCDK6#1: TRC number: TRCN0000196261, target sequence: GAGAAGTTTGTAAC AGATATC; shCDK6#2: TRCN0000055435, target sequence: TCTGGAGTGTTGGCTGCATAT) were obtained from SigmaAldrich. A scramble shRNA (Sigma-Aldrich, #SHC016) was used as negative control, its sequence was: GCGCGATAGCG CTAATAATTT. To generate virus, 293T cells were seeded in each 10 cm dish (Corning Inc.) and incubated at 37°C in a 5% CO 2 humidified atmosphere. After 24 h, the scramble and shRNA constructs targeting CDK4 or CDK6 (10 μg each), packaging plasmid (pCMV-dR8.91; 5 μg) and envelope plasmid (pMD2.G-VSV-G; 5 μg) were diluted with 1.0 mL Opti-MEM medium (Gibco, Invitrogen, Carlsbad, CA, USA), and then 60 μL of linear polyethylenimine transfection reagent (1.0 mg·mL À1 ) from Polysciences (Warrington, PA, USA) was added and the samples incubated for 15 min at room temperature. Subsequently, the transfection mixture was applied to each culture dish. Twelve hours after transfection, the culture medium was changed with fresh culture medium. Fourty-eight hours later, the virus-containing supernatants were collected and used to infect ESCC cells in the presence of 8 μg·mL À1 polybrene (Sigma-Aldrich). The cells were then selected in the presence of puromycin (1 μg·mL
À1
; Sigma-Aldrich) to establish stable clones. Immunoblotting for CDK4 and CDK6 was performed to determine the knockdown efficiency.
Transfection with plasmid or siRNA ESCC cells were seeded in 6-well flat-bottom plates (Corning Inc.) 24 h before transfection. The empty vector or pCMV6-Entry-FOXM1 (OriGene) plasmid (2.0 μg) and 6 μL linear polyethylenimine transfection reagent (1.0 mg·mL À1 ) from Polysciences (Warrington, PA) were added into 200 μL Opti-MEM medium (Gibco). Subsequently, the transfection mixture was applied to the culture plates. Twelve hours after transfection, the culture medium was replaced with fresh culture medium, and then the ESCC cells were selected using G418 (800 μg·mL À1 ; Invitrogen, CA, USA). After 4-weeks of selection, individual colonies were selected and expanded. For siRNA transfection, two different FOXM1 small interfering RNAs (siRNAs) and a non-silencing control siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Exponentially grown untreated cells were plated in a 6-well flat-bottom plates (Corning Inc.) and grown for 24 h before transfection. Plated cells were transfected with FOXM1 siRNAs or a control siRNA. Fourty-eight hours later, the cells were harvested and processed for further analysis.
Mouse models of tumour growth and metastasis
Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . The experimental procedures were also conducted in compliance with the Jinan University Institutional Animal Care and Use Committee and the guidelines on the welfare and use of animals in cancer research (Workman et al., 2010) . All animal care and experimental protocols were approved by the Jinan University Institutional Animal Care and Use Committee. Male nude nu/nu BALB/c mice (18-20 g, 5-6 weeks of age) were purchased from Slac Laboratory Animal Co. Ltd (Shanghai, China). All mice were bred and maintained in pathogen-free conditions at the animal facility of Jinan University with controlled temperature (20 ± 2°C), humidity (40-50%) and a lighting cycle of 12 h light/12 h darkness. Mice were housed in isolator cages (four mice per cage). Standard pellet food and water were provided ad libitum during the experimental period. EC109 cells (5 × 10 6 cells in PBS suspension) were implanted s.c. into the flank of each mouse (Wang et al., 2015) . Tumours were measured every other day and calculated by the formula of a × b 2 × 0.4, where a is the smallest diameter and b is the diameter perpendicular to a. When the tumours reached 100 mm 3 , the mice were randomly separated into two groups: vehicle or treatment (eight mice per group). PD-0332991 dissolved in sodium lactate buffer (50 mM, pH = 4.0) was administered daily at 150 mg·kg À1 by gavage. The control mice received the same amount of sodium lactate buffer solution. After 2 weeks of PD-0332991 treatment, mice were anaesthetized with isoflurane before being killed by cervical dislocation. Tumours were immediately removed, weighed, fixed and kept at À80°C. The body weight, feeding behaviour and motor activity of each animal were monitored as an indicator of general health. For the experimental metastasis assay, two groups of mice (n = 6 per group) were injected with KYSE150 cells (1 × 10 6 in PBS) i.v., via the lateral tail vein as previously described (Li et al., 2009 ). Twenty-four hours later, the animals were treated with PD-0332991 (150 mg·kg À1 by gavage) or vehicle for 2-weeks. Six weeks after the injection of cells, mice were anaesthetized with isoflurane before being killed by cervical dislocation, and the lungs were removed and fixed in Bouin's solution (75% saturated picric acid, 25% formaldehyde and 5.0% acetic acid) overnight. The metastatic foci on the surface of the lung in each mouse were counted, and the presence of tumour lesions within the lungs was confirmed by haematoxylin and eosin staining.
Statistical analysis
All experiments were performed at least five times, and data are expressed as mean ± SD. Student's t-test was used to compare the differences between two groups. We compared more than two groups with one-way ANOVA with Tukey's post hoc test, the overall F test was significant (P < 0.05), and there was no significant variance in homogeneity. GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA) was employed to conduct the statistical analysis. All statistical tests were two-sided, and P < 0.05 was considered statistically significant. The data and statistical analyses comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Materials and reagents
PD-0332991 was purchased from Selleck Chemicals (Shanghai, China). Cisplatin and 5-FU were purchased from Sigma-Aldrich. Antibodies and their sources are as follows: antibodies against Rb, phospho-Rb (Ser 780 ), phospho-Rb (Ser 807/811 ) and p16 were purchased from Cell Signaling Technology (Beverly, MA, USA); antibodies against (ADPribose) polymerase (PARP), Bcl-2, X-linked inhibitor of apoptosis (XIAP), active caspase-3 and cytochrome c were from BD Biosciences Pharmingen (San Jose, CA, USA); antibodies against CDK4, CDK6, cyclin A, cyclin E, FOXM1, Bax, Bcl-xL, Mcl-1 (S-19) and Bcl-2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-rabbit immunoglobulin G and anti-mouse immunoglobulin G fluorescent-conjugated secondary antibodies were obtained from LI-COR Biotechnology (Nebraska, USA).
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b) .
Results
PD-0332991 induces cellular Rb dephosphorylation and G1-phase arrest in ESCC cells
The ability of PD-0332991 to inhibit CDK4/6 was examined in ESCC cells by detecting CDK4/6-specific phosphorylation of Rb on Ser 780 . As shown in Figure 1A , PD-0332991 treatment down-regulated Rb phosphorylation as well as E2F target genes including cyclin A and cyclin E in a concentration-dependent fashion. However, the expression of total Rb, CDK4 and CDK6 were constant. These results suggest that PD-0332991 markedly inhibits CDK4/6 kinase activity. If PD-0332991 inhibited the activity of CDK4/6, then it was predicted to arrest cells at the G1-phase of the cell cycle. Indeed, EC109 and EC9706 cells largely remained in G1-phase upon PD-0332991 treatment ( Figure 1B ). In this experiment, the growth arrest of cells treated with nocodazole alone, which blocked cell cycle in G2-phase, was compared with cells pretreated with PD-0332991 for 8 h, then co-treated with PD-0332991 and nocodazole for another 16 h. Pretreatment with PD-0332991 resulted in a significant increase in G1-phase arrest for both groups of ESCC cells. Collectively, these results suggest that PD-0332991 can inhibit CDK4/6 kinase activity and halt the cell cycle at the G1-phase in ESCC cells.
PD-0332991 inhibits the growth of ESCC cells
To evaluate the inhibitory effect of PD-0332991 on cell proliferation, seven lines of ESCC cells were treated with different concentrations of PD-0332991 for 72 h, and cell viability was measured by the MTS assay. PD-0332991 potently decreased the cell viability of ESCC cells, with IC 50 values ranging from 11.42 to 20.15 μM ( Figure 1C ). We next determined the effect of PD-0332991 on the clonogenicity of ESCC cells. EC109, EC9706 and KYSE30 cells were exposed to increasing concentrations of PD-0332991 for 48 h and were then assayed for colony formation in the absence of drugs. PD-0332991 potently inhibited the number of surviving clonogenic ESCC cells in a dose-dependent manner ( Figure 1D ). Taken together, PD-0332991 potently inhibits the growth of ESCC cells in a dose-dependent manner.
PD-0332991 induces apoptosis in ESCC cells
We next analysed the capacity of PD-0332991 to induce apoptosis in ESCC cells. EC109 and EC9706 cells were treated with PD-0332991 for 48 h, and apoptosis was assessed using flow cytometry by annexin V-FITC/PI double staining. As shown in Figure 2A , PD-0332991 led to significant apoptotic cell death in a concentrationdependent fashion in both lines of ESCC cells. Moreover, PD-0332991 could also induce apoptosis in a timedependent manner (Supporting Information Figure S1A ).
Western blotting results showed a concentration-and time-dependent cleavage of PARP and caspase-3, further indicating the occurrence of apoptosis in EC109 and EC9706 cells treated with PD-0332991 ( Figure 2B and Supporting Information Figure S1B ).
To elucidate the mechanism of PD-0332991-induced apoptosis, we next evaluated the effect of PD-0332991 on apoptosis-related protein levels by Western blotting analysis. The results show that the levels of anti-apoptotic proteins survivin, Bcl-xL, Bid, XIAP and Bcl-2 were markedly declined, whereas the level of pro-apoptotic protein Bax was elevated ( Figure 2C and Supporting Information Figure  S1C) . Interestingly, the expression of anti-apoptotic protein Mcl-1 was not significantly changed even with 20 μM PD-0332991 treatment ( Figure 2C and Supporting Information Figure S1C ). The disturbance of these mitochondrial proteins prompted us to explore the effect of PD-0332991 on mitochondrial potential. EC109 and EC9706 cells were exposed to increasing PD-0332991 concentrations for 24 h. The proportion of ESCC cells with loss of mitochondrial potential detected by flow cytometry after staining with CMXRos and MTGreen was markedly increased ( Figure 2D ). The mitochondrial transmembrane potential change coincided with other apoptotic indices such as caspase-3 activation and PARP cleavage ( Figure 2B and Supporting Information Figure S1B ).
Next, we examined the release of cytochrome c from mitochondria into the cytosol. EC109 and EC9706 cells were treated with PD-0332991, and a progressive elevation of cytochrome c in cytosolic fractionations extracted using the digitonin buffer was noted (Figure 2  E) . Collectively, these data suggest that PD-0332991 may trigger apoptosis through the intrinsic (mitochondrial) pathway in ESCC cells.
PD-0332991 suppresses the migration and invasion of ESCC cells
We next determined the effect of PD-0332991 on wound healing ability. The migration ability of EC109 and EC9706 cells that were treated with PD-0332991 at 5 μM for 24 h was significantly inhibited, the inhibitory effect of PD-0332991 was further evident at 48 h ( Figure 3A) . Moreover, the Boyden chamber transwell assay also showed that the migration ability of both lines of ESCC cells was significantly impaired by PD-0332991 at the concentration of 5 μM ( Figure 3B ). We also analysed whether PD-0332991 could inhibit cell invasion by conducting transwell invasion assays. As shown in Figure 5E , PD-0332991 strongly inhibited the invasion of EC109 and EC9706 cells ( Figure 3C ).
Matrix metalloproteinases (MMPs), a family of zincdependent proteolytic enzymes capable of degrading the extracellular matrix, play a key role in tumour invasion and metastatic processes in various types of cancer including ESCC . We therefore tested whether PD-0332991inhibited the expression of MMP-2 and MMP-9, two critical members of the MMP family, in EC109 and EC9706 cells. Western blotting analysis indicated that PD-0332991 dramatically decreased the protein level of MMP-2 with minimal impact on MMP-9 ( Figure 3D ). Taken together, these data indicate that PD-0332991 inhibits MMP-2 expression, as well as the migration and invasion of ESCC cells.
CDK4/6 shRNA attenuates ESCC cell proliferation, migration and invasion
To specifically characterize the effect of CDK4 and CDK6 inhibition, EC109 and EC9706 cells were stably transduced with lentiviruses encoding shRNA against CDK4, CDK6 or a scrambled control; a decrease in CDK4 and CDK6 in the cells transduced with shRNA against CDK4, CDK6 or the combination was observed by immunoblotting ( Figure 4A ). In comparison with scramble, specific knockdown of CDK4 alone just had a very weak inhibitory effect on ESCC cells. Silencing CDK6 on its own significantly suppressed the anchorage-independent growth of EC109 and EC9706 cells. In contrast, the inhibitory effect was markedly enhanced after knockdown of both CDK4 and CDK6 ( Figure 4B ). Similarly, simultaneously silencing CDK4 and CDK6 markedly diminished the wound healing ability of EC109 and EC9706 cells ( Figure 4C ). The inhibitory effect of knockdown of both CDK4 and CDK6 on migration was further confirmed by the transwell migration assay ( Figure 4D ). Moreover, knockdown of both CDK4 and CDK6 significantly halted the transwell invasion capacity ( Figure 4E) . Additionally, the level of MMP-2 was markedly decreased in ESCC cells transduced with lenti-shRNA against both CDK4 and CDK6 ( Figure 4F ). These findings suggest that, like PD-0332991, specifically knocking down both CDK4 and CDK6 diminishes the aggressiveness of ESCC cells.
PD-0332991 induces ESCC cell senescence by inhibiting FOXM1
Previous studies have shown that prolonged incubation with PD-0332991 can induce senescence-like morphological changes in glioblastoma, osteosarcoma (Anders et al., 2011) , melanoma , fibrosarcoma and breast cancer cells (Dean et al., 2010) . We therefore investigated whether PD-0332991 induced senescence in ESCC cells or not. As shown in Figure 5A , treatment with PD-0332991 drastically increased the activity of SA-β-gal, a marker for senescent cells in EC109 and EC9706 cells. Because forkhead box M1 (FOXM1), a critical substrate of CDK4/6 signalling, plays a key role in protecting tumour cells from senescence (Anders et al., 2011; Wang et al., 2011) , we examined whether it is involved in PD-0332991-mediated senescence in ESCC cells. Western blotting analysis revealed that the protein level of FOXM1 was decreased by PD-0332991 in a concentration-dependent manner ( Figure 5B ). To further substantiate the involvement of FOXM1, we reconstituted ESCC cells with FOXM1 plasmid ( Figure 5C ). Enforced expression of FOXM1 attenuated PD-0332991-induced cell senescence in EC109 and EC9706 cells Knockdown of CDK4/6 inhibits the proliferation and migration of ESCC cells. (A) Western blotting analysis of CDK4 and CDK6, as well as the phosphorylated and total levels of Rb in EC109 and EC9706 cells stably transfected with the indicated shRNA. (B) Tumourigenicity was detected by colony formation in ESCC cells that was stably knocked down for CDK4/6 by shRNA (n = 6 per group). shCON: control shRNA; shCDK4#1 and shCDK4#2: two different shRNAs targeting CDK4; shCDK6#1 and shCDK6#2, two different shRNAs targeting CDK6; shCDK4/6, both CDK4 and CDK6 shRNA. * P < 0.05 versus shCON; # P < 0.05 versus shCDK4/6; P values were obtained by one-way ANOVA with post hoc intergroup comparison by the Tukey's test. (C-E) Wound healing (C), transwell migration (D) and invasion (E) assays of EC109 and EC9706 cell stable clones with knockdown of CDK4, CDK6 alone or both (n = 6 per group). Scale bar for wound healing: 200 μm. *, P < 0.05 versus shCON; #, P < 0.05 versus shCDK4/6; P values were obtained by one-way ANOVA with post hoc intergroup comparison with Tukey's test. (F) Western blotting analysis of MMP-2 and MMP-9 expression in CDK4/6-knockdown ESCC cells by shRNA. Actin served as a loading control. ( Figure 5D, E) . By contrast, there was no significant difference between cells transfected with empty vector and FOXM1-encoding plasmid ( Figure 5D , E). However, silencing FOXM1 with two different FOXM1siRNA duplexes resulted in a substantial increase in basal senescence ( Figure 5F-H) . Importantly, compared with si-control transfection, knockdown of FOXM1 obviously potentiated the PD-0332991-induced cellular senescence, as indicated by a significant increase in the percentage of SA-β-gal positive cells ( Figure 5G, H) . These results suggest that PD-0332991 may trigger ESCC cell senescence by inhibiting FOXM1.
PD-0332991 is synergistic with 5-FU and cisplatin
Given that the combination of molecule-targeted therapeutic agents and conventional therapeutic agents is an effective strategy to improve the quality of life of ESCC patients (Ekman et al., 2008) , we next explored whether there was a synergy between PD-0332991 and the front-line chemotherapeutic agents for ESCC, 5-FU and cisplatin, at inhibiting the growth of the cells. EC109 and EC9706 cells were treated with a serially diluted mixture (at a fixed ratio) of PD-0332991 and 5-FU or cisplatin for 72 h; cell viability was detected by MTS assay, and the synergistic effect was evaluated using the median-effect method of Chou and Talalay (Chou, 2010) . The results suggest that PD-0332991 acts synergistically with both drugs in causing growth inhibition of ESCC cells ( Figure 6A ). Using another approach, EC109 and EC9706 cells were exposed to PD-0332991 (10 μM) in combination with 5-FU (200 μM) or cisplatin (12.5 μM) for 48 h, and the number of live cells was counted with the trypan blue exclusion assay. As shown in Figure 6B , D, 5-FU exhibited no toxic effects on ESCC cells, and either PD-0332991 or cisplatin induced minimal lethality. However, the combination treatments of PD-0332991 and 5-FU or cisplatin led a significantly enhanced ratio of dead cells (Figure 6B, D) . Consistent with these results, Western blotting results also showed that the combinations of PD-0332991 and 5-FU or cisplatin led to enhanced apoptosis, as indicated by specific cleavage of PARP ( Figure 6C, E) . These findings encourage a combination regimen of PD-0332991 and 5-FU/cisplatin for the treatment of ESCC patients.
PD-0332991 inhibits ESCC cell growth and metastasis in nude mice
To evaluate the in vivo effect of PD-0332991, we inoculated nu/nu BALB/c nude mice with EC109 cells s.c. Six days later, when the tumour xenografts were palpable (about 100 mm 3 ), the mice were randomly divided into two groups:
vehicle or PD-0332991 (eight mice per group; 150 mg·kg À1 , oral gavage, daily) for about 2 weeks. The growth curve (tumour volume versus time curve) of EC109 tumours was significantly inhibited by the PD-0332991 treatment ( Figure 7A ). In addition, the tumour weight in the PD-0332991-treated mice was significantly lower than the vehicle-treated mice ( Figure 7B ). Furthermore, assessment of the Ki67 proliferation marker by immunohistochemistry showed that the proliferation of EC109 cells was significantly impaired by PD-0332991 ( Figure 7C ). Moreover, tumours in the PD-0332991-treated animals demonstrated an increase in active caspase-3 (an indicator of apoptotic cell death) compared with those from the vehicle-treated mice ( Figure 7C ). The level of phospho-Rb was substantially diminished in the PD-0332991-treated group, which indicates that PD-0332991 inhibited the activity of CDK4/6 kinase ( Figure 7C ). Consistent with these results, Western blotting analysis of cell lysates from xenografted tumours showed that PD-0332991 dramatically inhibited the phospho-Rb levels, while the total amount of Rb protein was not altered ( Figure 7D) . Notably, analysis of tumour tissues also demonstrated that PD-0332991 markedly decreased FOXM1 expression but increased p16 protein which is a senescence marker ( Figure 7D ). Tumour metastasis is one of the important reasons that patients with ESCC often have a poor survival rate. Because CDK4/6 inhibition decreased the migration and invasive potential of ESCC cells in vitro, we next evaluated the effect of PD-0332991 on metastasis of ESCC cells in vivo. Compared with vehicle treatment, PD-0332991 significantly attenuated the activity of lung metastasis in nude mice, as evidenced by the decreased number of metastatic tumour nodules in the lungs ( Figure 7E ). Moreover, histological analysis also revealed an appreciable decrease in size and number of metastatic foci in the lungs of PD-0332991-treated mice, compared with that of the vehicle-treated mice ( Figure 7F ). These results therefore support the possibility that PD-0332991 can inhibit the growth and metastasis of ESCC cells in vivo.
Discussion
In this study, we analysed the inhibitory effect of PD-0332991 on ESCC cells in vitro and in vivo. We found that PD-0332991 significantly suppressed the growth, migration and invasion of ESCC cells. The expression of MMP-2 was simultaneously down-regulated. Moreover, knockdown of CDK4/6 using shRNA mimicked the inhibitory effects of PD-0332991 on cell growth, migration and invasion. PD-0332991 treatment also triggered ESCC cell senescence by decreasing FOXM1 expression. In addition, PD-0332991 displayed a synergistic effect on cell growth inhibition with cisplatin or 5-FU. More importantly, the in vivo studies also demonstrated that PD-0332991 can inhibit the growth and metastasis of ESCC cells in nude mice, which was consistent with the findings from our in vitro study. To our knowledge, this is the first report to elucidate the role of PD-0332991 in ESCC cells, using both in vitro and in vivo models.
PD-0332991 is an orally active, water soluble cellpermeable pyridopyrimidine, that potently inhibits the activity of recombinant CDK4 and CDK6 (IC 50 = 11-15 nM) by competing with ATP-binding sites (Fry et al., 2004) . The anti-proliferative effects of PD-0332991 have been demonstrated in a number of preclinical studies (Fry et al., 2004; Finn et al., 2009; Konecny et al., 2011) . PD-0332991 was reported to induce the cell cycle arrest at G1-phase by suppressing phosphorylation of Rb tumour suppressor protein (Malumbres and Barbacid, 2009) . Rb phosphorylation facilitates the release of Rb from E2F transcription factor, enabling E2F to transcribe the genes that are required for cell cycle progression from the G1 to the S phase and ultimately for cellular proliferation (Musgrove et al., 2011; Reynolds et al., 2014) . In this study, our data also showed that Rb phosphorylation was inhibited and the cell cycle was blocked at the G1-phase by PD-0332991. The MTS and clonogenicity assays also confirmed that PD-0332991 prevented the proliferation of ESCC cells at low concentrations. Furthermore, our in vivo data revealed that PD-0332991, at an oral dose of 150 mg·kg À1 ·day À1 , potently inhibited the growth of xenografted EC109 cells, and markedly suppressed Rb phosphorylation, suggesting that PD-0332991 may be an attractive therapeutic candidate for ESCC. In addition, PD-0332991 induced apoptosis in ESCC cells, as demonstrated by annexin V binding, specific cleavage of PARP and activation of caspase-3. The apoptosis was triggered by the mitochondrial-dependent pathway because PD-0332991 evoked the release of cytochrome c into the cytosol. The levels of survivin, XIAP, Bcl-2 and Bcl-xL were decreased in PD-0332991-mediated apoptotic Figure 6 PD-0332991 is synergistic with cisplatin and 5-FU. (A) EC109 and EC9706 cells were incubated in a serially diluted mixture (a fixed ratio) of PD-0332991 and cisplatin or 5-FU for 72 h; the cell viability was determined by MTS assay. The synergistic effect was estimated using the medianeffect method of Chou and Talalay. The CI was the ratio of the combined dose to the sum of the single-agent doses at an isoeffective level. CI < 1 indicates synergy; CI > 1, antagonism; and CI = 1, additive. (B, D) EC109 and EC9706 cells were exposed to PD-0332991 (10 μM) combined with 5-FU (200 μM) or cisplatin (12.5 μM) for 48 h and then examined with a haemocytometer by trypan blue exclusion assay (n = 6 per group). Column, mean; error bar, SD. * P < 0.05, one-way ANOVA with post hoc intergroup comparison with Tukey's test. (C, E) The cleavage of PARP was detected by Western blotting analysis. + indicates the presence, and -indicates the absence of the drugs. ESCC cells. Consistent with our results, it is reported that disruption of the cyclinD1/CDK4 complex by chemical inhibitors can reduce the expression of the ant-apoptotic survivin (Baughn et al., 2006; Retzer-Lidl et al., 2007) . Future work needs to further define the precise mechanism of this effect of PD-0332991. ESCC has a poor prognosis because invasion and metastasis are prevalent. In this study, we found that PD-0332991 inhibited ESCC cell migration and invasion and decreased the expression of MMP-2. Consistent with our results, it was shown that PD-0332991 inhibits breast cancer cell migration and invasion in both ER-positive (T47D) and -negative (MDA-MB-231) cells (Qin et al., 2015) . However, a previous report has shown that CDK4/6 inhibition by PD-0332991 can induce epithelial-mesenchymal transition and enhance invasiveness in pancreatic cancer cells by activating Smaddependent TGF-β signalling (Liu and Korc, 2012) . Taken together, these findings suggest that whether PD-0332991 inhibits or induces migration and invasion may depend on the tumour context. CDK4 and CDK6, being highly homogeneous, can be bound and activated by the D-type cyclins (cyclin D1, D2 and D3). In this respect, their functions may be redundant. Indeed, previous reports have shown that mice deficient in CDK4 are viable and only display proliferative defects in specific endocrine cell types, an observation attributed to a putative compensatory role by CDK6 (Martin et al., 2003) . Similarly, CDK6-knockout mice are viable and develop normally despite a slightly impaired haematopoiesis (Malumbres et al., 2004) , whereas CDK4/CDK6 double-knockout embryos die during the late stages of embryonic development due to severe anaemia (Malumbres et al., 2004) . Moreover, in oesophageal adenocarcinoma (EAC), a combined model of both CDK6 and CDK4 expression is a superior predictor of survival over either alone. Specific knockdown of CDK4 and/or CDK6 in EAC cells by siRNAs demonstrated that their function is additive (Ismail et al., 2011) . Consistently, our results revealed that the combined knockdown of both CDK4 and CDK6 led to a stronger suppression of ESCC cell growth, migration and invasion than knockdown of either CDK4 or CDK6 alone. These experiments are consistent with previous studies showing that CDK4 and CDK6 have redundant roles in controlling the G1 to S transition and proliferation (Malumbres et al., 2004) . Together, our data further suggest the functional redundancy of CDK4 and CDK6 and highlight the requirement of simultaneous inhibition of CDK4 and CDK6 for suppression of ESCC.
Cellular senescence is a tumour-suppressive mechanism, which must be overcome during cell immortalization and transformation (Anders et al., 2011) . Prolonged incubation with PD-0332991 has been shown to induce a senescence-like morphological change in melanoma, glioblastoma and breast cancer cells, as indicated by enhanced activity of SA-β-Gal (Dean et al., 2010; Michaud et al., 2010; Anders et al., 2011) . In this study, we found that treatment with PD-0332991 induced cellular senescence in EC109 and EC9706 cells. FOXM1 is a forkhead box family transcription factor that regulates the transcription of cell cycle genes critical for progression into S-phase and mitosis. A previous study has indicated that early-passage FOXM1 À/À mouse embryonic fibroblasts display premature senescence (Wang et al., 2005) . Moreover, a systematic screen for CDK4/6 substrates has demonstrated that FOXM1 is a potential target of CDK4/6 signalling, and CDK4/6 can stabilize and activate FOXM1 to protect cancer cells from senescence (Anders et al., 2011) . Consistent with these reports, our results showed that the decrease in FOXM1 by PD-0332991 in ESCC cells might facilitate cellular senescence, because forced expression of FOXM1 protected ESCC cells against senescence in response to PD-0332991, which is in line with the previous finding showing that FOXM1 exhibits senescence-suppressing activity (Wang et al., 2005) . However, silencing FOXM1 with siRNAs resulted in a substantial increase in basal senescence. Of importance, FOXM1 knockdown further enhanced PD0332991-induced SA-β-Gal activities in EC109 cells. These findings may strengthen the rationale for the treatment of ESCC with small molecule inhibitors of CDK4/6. In contrast, Lian et al. did not observe senescence following PD-0332991 treatment in ESCC cells (Lian et al., 2015) . The possible reasons might include shorter exposure of ESCC cells to PD-0332991 and the different lines (TE7, TE8 and TE10) used in their system. It is widely recognized that combination approaches to therapy are helpful for making targeted agents successful in the treatment of ESCC (Ekman et al., 2008) . There are numerous preclinical data regarding the synergy between PD-0332991 and anti-oestrogen agents including tamoxifen, trastuzumab in breast cancer (Perou et al., 2000; Finn et al., 2009) . Moreover, PD-033299, when used in combination with cytotoxic drugs, such as bortezomib and dexamethasone, markedly enhances the killing of myeloma cells by the cytotoxic agents (Baughn et al., 2006; Menu et al., 2008) . In agreement with these findings, we found a notable synergistic antiproliferative effect between PD-0332991 and 5-FU or cisplatin in ESCC cells. During the revision of this manuscript, Zhou et al. reported that an increase in cell cycle-related genes including CDK6 and cyclin D1 accompanies the amplification of the EGFR gene in primary ESCC tumours, and that blocking CDK4/6 activity with PD-0332991 can prevent the resistance of these cells to the EGFR inhibitor erlotinib in vitro and improve the response of both OE21 and KYSE140 xenografts to erlotinib (Zhou et al., 2017) . Taken together, dual inhibition of CDK4/6 by PD-0332991 in combination with either cytotoxic chemotherapy or targeted therapy might be a promising strategy for ESCC patients.
Conclusion
In conclusion, PD-0332991, a potent inhibitor of CDK4 and CDK6, inhibits cell growth, induces apoptosis and senescence and suppresses migration, invasion and metastasis in ESCC cells. Our results warrant a clinical trial to further evaluate its efficacy in ESCC patients, even in those with metastasis.
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https://doi.org/10.1111/bph.13836 Figure S1 Time-course observation of apoptosis in ESCC cells after treatment with PD-0332991. (A) EC109 and EC9706 cells were treated with 20 μM PD-0332991 for indicated durations, flow cytometry analysis was used to detect the cell death after staining with annexin V-FITC/PI. Data were expressed as mean ± SD (n = 5 per group). *, P < 0.05, one-way ANOVA with post hoc intergroup comparison with the Tukey's test. (B) and (C) Immunoblotting of apoptosis-related proteins was shown in EC109 and EC9706 cells treated with 20 μM PD-0332991.
